Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Consensus on the diagnosis and treatment of unresectable stage III driver gene-positive non-small cell lung cancer.

Cancer letters - 28 Feb 2026

Meng Xiangjiao, Bi Nan, Wang Jun, Meng Xue, Wang Jianbo, Xing Ligang, Cheng Yufeng, Lu Shun, Chen Ming, Yu Jinming

Abstract excerpt

Unresectable stage III non-small cell lung cancer (NSCLC) exhibits substantial heterogeneity and complexity. The landmark LAURA and POLESTAR studies have established a standard therapeutic model involving targeted consolidation therapy with osimertinib or aumolertinib after definitive chemoradiotherapy for NSCLC patients harboring EGFR-sensitive mutations. However, treatment strategies for patients with other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ALK gene

Share to EGFR gene

Share to ROS1 gene

Share to Lung Neoplasms

Share to Mutation

Share to Neoplasm Staging

Source

Identifiers

PMID: 41419100
DOI: 10.1016/j.canlet.2025.218223

Genes

ALK
EGFR
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Consensus on the diagnosis and treatment of unresectable stage III driver gene-positive non-small cell lung cancer.PMID 41419100Read ↗

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.Semantic proximity Read ↗

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.Semantic proximity Read ↗

[Chinese Expert Consensus on Second-line Treatment for Non-small Cell Lung Cancer with Negative Driver Gene Mutations].Semantic proximity Read ↗

Comparison of efficacy and safety of first-line treatment options for unresectable stage III non-small cell lung cancer: a retrospective analysisSemantic proximity Read ↗

NSCLC: An Update of Driver Mutations, Their Role in Pathogenesis and Clinical Significance.Semantic proximity Read ↗

Best Practices for the Multidisciplinary Care of Patients With Early-Stage Driver-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Treatment Patterns and Clinical Outcomes in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer in China.Semantic proximity Read ↗

[Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer].Semantic proximity Read ↗

Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario.Semantic proximity Read ↗

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.Semantic proximity Read ↗

Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion.Semantic proximity Read ↗

Optimizing management of stage IV EGFR mutant non‐small cell lung cancer in Asia: An expert opinionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.